Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080892 | 0.88 | LMNA (0.38) | LMNAKMT2APOLB | |
| SCHEMBL7615093 | 0.81 | LMNA (0.37) | LMNAKMT2APOLB | |
| SCHEMBL7617669 | 0.81 | MEN1 (0.39) | KMT2A | |
| SCHEMBL7080896 | 0.80 | POLB (0.43) | LMNAKMT2APOLB | |
| SCHEMBL7081235 | 0.78 | LMNA (0.44) | LMNAKMT2A | |
| SCHEMBL7080891 | 0.74 | LMNA (0.36) | LMNAKMT2A | |
| SCHEMBL7082203 | 0.74 | — | — | |
| SCHEMBL7085230 | 0.74 | LMNA (0.41) | LMNAKMT2A | |
| SCHEMBL7085245 | 0.73 | LMNA (0.40) | LMNAKMT2AALDH1A1 | |
| SCHEMBL7085491 | 0.73 | LMNA (0.37) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | HDAC1 325/4885LMNA 2706/4885KMT2A 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.